Marker Therapeutics, Inc.

3200 Southwest Freeway, Suite 2500

Houston, Texas 77027

 

August 17, 2021

 

Via EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:		Lauren S. Hamill
Re:		Marker Therapeutics, Inc.
		Registration Statement on Form S-3 (File No. 333-258687)
		Request for Acceleration of Effective Date

 

Ms. Hamill:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-258687) (the “Registration Statement”) to become effective on August 19, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.

 

Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, Owen Williams at (202) 842-7843.

 

[Signature page follows]

 

 

	Very truly yours,
	Marker Therapeutics Inc.
	By:	/s/ Peter Hoang
		Peter Hoang
		President and Chief Executive Officer

 

cc:
	Anthony Kim, Marker Therapeutics, Inc. Michael Loiacono, Marker Therapeutics, Inc.
	Divakar Gupta, Cooley LLP
	Darren DeStefano, Cooley LLP
	Owen Williams, Cooley LLP

 

Signature Page to Company Acceleration Request – S-3